Eli Lilly And Company (LLY) closed at $1437.29 on November 11, 2026, up 0.3% from the previous close, on volume of 1,681,548 shares (30-day average 2,716,497).
Data as of November 11, 2026.
11-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 3, 2026 | Put Butterfly | 19-Mar-27800 : 1000[2x] : 1200 P | 3,216 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
China approves Eli Lilly's GLP-1 weight-loss pill, giving it lead over Novo - report
Seeking Alpha News (Thu, 12-Nov 4:48 AM ET)
Democratic senators probe gifts to RFK Jr. from large donor to his presidential campaign
Seeking Alpha News (Wed, 11-Nov 3:39 PM ET)
PRNewswire (Wed, 11-Nov 9:45 AM ET)
3 Mega-Cap Stocks with a ‘Perfect 10’ Smart Score
TipRanks (Wed, 11-Nov 9:11 AM ET)
TipRanks (Wed, 11-Nov 8:50 AM ET)
4 stocks to watch on Wednesday: LLY, BABA, PYPL, and NVDA
Seeking Alpha News (Wed, 11-Nov 8:47 AM ET)
Apple Shares (AAPL) Look Expensive Heading into 2027
TipRanks (Wed, 11-Nov 8:15 AM ET)
Lilly sued over alleged firing of sales rep for complaints about Mounjaro misbranding
Seeking Alpha News (Wed, 11-Nov 7:12 AM ET)
Hims & Hers Health Faces Legal Woes as Five States Join FTC Lawsuit over Privacy Practices
TipRanks (Wed, 11-Nov 3:59 AM ET)
TipRanks (Tue, 10-Nov 1:06 PM ET)
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Eli Lilly And Company trades on the NYSE stock market under the symbol LLY.
As of November 11, 2026, LLY stock price climbed to $1,437.29 with 1,681,548 million shares trading.
LLY has a beta of 0.02, meaning it tends to be less sensitive to market movements. LLY has a correlation of 0.00 to the broad based SPY ETF.
LLY has a market cap of $1.28 trillion. This is considered a Mega Cap stock.
Last quarter Eli Lilly And Company reported $24 billion in Revenue and $7.48 earnings per share. This beat revenue expectation by $2 billion and exceeded earnings estimates by $1.12.
In the last 3 years, LLY traded as high as $1,453.00 and as low as $561.65.
The top ETF exchange traded funds that LLY belongs to (by Net Assets): VTI, VOO, IVV, SPY, VUG.
LLY has outperformed the market in the last year with a price return of +49.4% while the SPY ETF gained +12.6%. LLY has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +16.8% and +12.1%, respectively, while the SPY returned -1.5% and -1.3%, respectively.
LLY support price is $1,399.88 and resistance is $1,464.70 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LLY shares will trade within this expected range on the day.
